TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04429139
Drug: photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
Study: NCT01588548
Drug: AZD1208
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
Study: NCT03735225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Dasiglucagon injection
Study: NCT00368355
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: day-7 and day-6~45 mg/kg
Study: NCT03305822
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00804999
Drug: Clear Care
Normalized name: Clear care plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: neutralized Clear Care
Study: NCT01252108
Drug: SQ109
Normalized name: SQ109
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg SQ109 daily for 14 days
Study: NCT01991028
Drug: Radiolabelled OligoG CF-5/20 DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation with dry powder by Mia Monodose Inhaler
Study: NCT01991028
Drug: Radiolabelled OligoG CF-5/20 6% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation with aerosolised solution by nebuliser
Study: NCT02177045
Drug: Sonovue, Bracco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT03600974
Drug: Probiotic Agent
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
Study: NCT03600974
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
Study: NCT03600974
Drug: Prokinetic Motility Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
Study: NCT03600974
Drug: Neuromodulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
Study: NCT01700192
Drug: Rescue Medication: Self-Injectable Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
Study: NCT02738515
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
Study: NCT00848081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: By mouth once daily for 12 weeks
Study: NCT00361153
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03415191
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
Study: NCT00660998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02635945
Drug: PBF-680
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02635945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00573469
Drug: D9421-C, 9mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: D9421-C 9 mg was given once daily for 8 weeks.
Study: NCT00573469
Drug: D9421-C, 15mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: D9421-C 15 mg was given once daily for 8 weeks.
Study: NCT00573469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: D9421-C matching placebo was given once daily for 8 weeks.
Study: NCT02064868
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
Study: NCT02442362
Drug: paclitaxel+oxaliplatin+fluorouracil
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14.
Study: NCT00188149
Drug: Combined chemotherapy (ABVD, BACOPP-D)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00754624
Drug: Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
Study: NCT01541124
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/pill, po, each 6h, during 6m
Study: NCT01320085
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04056689
Drug: DNL151
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT04056689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT02329561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
Study: NCT04566211
Drug: (panto+amox+clar+metr)+(panto+amox)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
Study: NCT01016054
Drug: Pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00268515
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02528409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04333134
Drug: SHR3162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
Study: NCT00005892
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01635101
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours
Study: NCT00434590
Drug: Enteric coated mycophenolate sodium (Myfortic®)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04163588
Drug: Loop Diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)
Study: NCT04791007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal or rectal administration
Study: NCT04129060
Drug: Cholinergic antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo
Study: NCT01234324
Drug: Epirubicin, Cisplatin, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
Study: NCT00851006
Drug: Creatine Monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creapure brand of creatine monohydrate
Study: NCT00003700
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I \& IV (pts \< 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II \& V
Study: NCT00003700
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Courses III \& VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX \<0.05 uM after ea IV dose
Study: NCT00003700
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/sq m/d PO every day Course VII
Study: NCT00003700
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15mg intrathecal Day 1 Courses II \& V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, \& 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III \& VI.
Study: NCT04083534
Drug: REGN5459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion
Study: NCT03495206
Drug: Y-2(Edaravone And Borneol) Sublingual Tablet
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
Study: NCT00754052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
Study: NCT02998606
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 25 mg, daily
Study: NCT00063609
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00359671
Drug: MK6592
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
Study: NCT02653391
Drug: Part A Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
Study: NCT02653391
Drug: Part B Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
Study: NCT01938599
Drug: AM001 Cream, 7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream, 2x daily for 12 weeks
Study: NCT01938599
Drug: Placebo of AM001 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream, 2x daily for 12 weeks
Study: NCT00557245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo TDF \& Placebo FTC/TDF, 1 tablet each daily.
Study: NCT03523650
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
Study: NCT01802216
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic microspheres
Study: NCT03971734
Drug: Regadensoson 0.1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadensoson 0.1mg administered prior to MRI
Study: NCT03971734
Drug: Regadensoson 0.2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadensoson 0.2mg administered prior to MRI
Study: NCT03971734
Drug: Regadensoson 0.4mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadensoson 0.4mg administered prior to MRI
Study: NCT03971734
Drug: Regadensoson 0.7mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadensoson 0.7mg administered prior to MRI
Study: NCT03971734
Drug: Regadensoson 1.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadensoson 1.0mg administered prior to MRI
Study: NCT03971734
Drug: Regadensoson 1.4mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadensoson 1.4mg administered prior to MRI
Study: NCT01713166
Drug: plasmalyte solution
Normalized name: Plasmalyte A
Approvals — FDA: no, EMA: no, PMDA: no
Description: plasmalyte solution
Study: NCT00440622
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
Study: NCT00683592
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00498316
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
Study: NCT04129944
Drug: UBX0101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug intra-articular injection
Study: NCT02714296
Drug: Nutridrink 200 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
Study: NCT02519543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be given twice daily, once with breakfast and once with supper
Study: NCT03023189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
Study: NCT03843125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04480307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
Study: NCT00570128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation matched to active treatment for oral administration.
Study: NCT02224053
Drug: AZD9291 tablet dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
Study: NCT00050076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
Study: NCT00376740
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
Study: NCT00842816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets to match ST101 tablets
Study: NCT02911935
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
Study: NCT02911935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension
Study: NCT00172016
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00001217
Drug: pre-surgical chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01745081
Drug: Hypertonic saline 3% bolus administration
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02608476
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Study: NCT02522780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Granules in sachet; Route of administration: Oral use
Study: NCT04066257
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline hydrochloride 250 mg capsule
Study: NCT02260635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00669435
Drug: Losartan + Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets; 50, 100 mg; od; 12 months~tablets; 20 mg; od; 6 months
Study: NCT00669435
Drug: Amlodipine + Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets; 5, 10 mg; od; 12 months~tablets; 20 mg; od; 6 months
Study: NCT01745887
Drug: EBI-005-2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
Study: NCT02729207
Drug: Esflurbiprofen Hydrogel Patch
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One patch per day for 7 days
Study: NCT02365909
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
Study: NCT01358253
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
Study: NCT01358253
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
Study: NCT01358253
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
Study: NCT02117505
Drug: Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
Study: NCT04145245
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
Study: NCT00959569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normosaline (same ml of the study drug)
Study: NCT02973581
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
Study: NCT00918307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
Study: NCT02311517
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02227550
Drug: Vitamin K antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
Study: NCT01266603
Drug: HDIL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
Study: NCT03901690
Drug: Betaglucin soluble gel 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
Study: NCT03079427
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
Study: NCT00959439
Drug: Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00959439
Drug: Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01801917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet for oral administration
Study: NCT01737944
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibex MTX Device
Study: NCT04615312
Drug: a CDK4 / 6 inhibitor and a MEK inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose
Study: NCT01845064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01747577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02735694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
Study: NCT05188924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00603512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT00603512
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT00603512
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT00603512
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT00603512
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg BID, 3 blinded tablets administered BID for 12 weeks